Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Exclusion Criteria

• •Pregnant or lactating female
• •Prior radiation therapy to the target lesion
• •Use of any investigational drug within 28 days or five half-lives, whichever is shorter, prior to the first dose of study medication; a minimum of 10 days between termination of the investigational drug and treatment with study medication is required
• •Any major radiotherapy, tumor-directed systemic or immunotherapy within the last 4 weeks for any indication
• •Candidate for therapeutic neoadjuvant treatment
• •Active infection
• •Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, or cardiac disease)
• •Required administration of concomitant moderate or strong inhibitors or inducers of CYP3A4 for 14 days prior to the first dose of study drug prior amiodarone for up to 6 months prior to day 1 of study treatment
• •Inability to take oral medications e.g., impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral medications (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
• •History or evidence of cardiovascular risk including any of the following:
• •* Current uncontrolled hypertension (systolic \>150 mm Hg and/or diastolic \>100 mmHg) or unstable angina
• •* History of serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia)
• •* History of myocardial infarction within 6 months of day 1 of dosing
• •* History of CHF of New York Heart Association (NYHA) criteria
• •Known human immunodeficiency virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
• •Have acute or currently active/requiring anti-viral therapy hepatic or biliary disease (with the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).
• •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs
• •Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
• •Any other concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol